Stocks › REVB
REVELATION BIOSCIENCES, INC.
REVB·Nasdaq·
United States·USD
United States·USD$0.83
+0.08 (+10.09%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
REVB
REVELATION BIOSCIENCES, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
REVBS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of REVB by members of U.S. Congress · 36 on record
Whale Activity
Position changes in REVB reported for 2026-06-30 by 2 tracked institutional filers
- Increased0
- New1
- Held0
- Decreased1
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| CITADEL ADVISORS LLC | 38.6K | $40K | new |
| CITADEL ADVISORS LLC | 18.7K | $116 | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by REVB insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
41 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Rolke JamesChief Executive Officer · Director | Tax withholding | −10.1K | $1.13 | $11K | Apr 30, 2026 | Form 4 ↗ |
| Zygmont Chester Stanley IIIChief Financial Officer | Tax withholding | −13.3K | $1.10 | $15K | Apr 30, 2026 | Form 4 ↗ |
| Zygmont Chester Stanley IIIChief Financial Officer | Tax withholding | −13.1K | $1.65 | $22K | Feb 4, 2026 | Form 4 ↗ |
| ROPER JESSDirector | Tax withholding | −1,591 | $1.85 | $3K | Feb 3, 2026 | Form 4 ↗ |
| Chawla Lakhmir SDirector | Tax withholding | −2,261 | $1.85 | $4K | Feb 3, 2026 | Form 4 ↗ |
| CARVER JENNIFERDirector | Tax withholding | −1,661 | $1.87 | $3K | Feb 3, 2026 | Form 4 ↗ |
| Rolke JamesChief Executive Officer · Director | Tax withholding | −8,521 | $1.86 | $16K | Feb 3, 2026 | Form 4 ↗ |
| Rolke JamesChief Executive Officer · Director | Grant / award | +532.8K | $0.90 | $480K | Jan 8, 2026 | Form 4 ↗ |
| Zygmont Chester Stanley IIIChief Financial Officer | Grant / award | +78.1K | $0.90 | $70K | Jan 8, 2026 | Form 4 ↗ |
| CARVER JENNIFERDirector | Grant / award | +42.0K | $0.90 | $38K | Jan 8, 2026 | Form 4 ↗ |
| ROPER JESSDirector | Grant / award | +42.0K | $0.90 | $38K | Jan 8, 2026 | Form 4 ↗ |
| Chawla Lakhmir SDirector | Grant / award | +42.0K | $0.90 | $38K | Jan 8, 2026 | Form 4 ↗ |
| Chawla Lakhmir SDirector | Grant / award | +15.6K | $1.28 | $20K | Oct 29, 2025 | Form 4 ↗ |
| Rolke JamesChief Executive Officer · Director | Grant / award | +390.6K | $1.28 | $500K | Oct 29, 2025 | Form 4 ↗ |
| CARVER JENNIFERDirector | Grant / award | +15.6K | $1.28 | $20K | Oct 29, 2025 | Form 4 ↗ |
| Zygmont Chester Stanley IIIChief Financial Officer | Grant / award | +390.6K | $1.28 | $500K | Oct 29, 2025 | Form 4 ↗ |
| ROPER JESSDirector | Grant / award | +15.6K | $1.28 | $20K | Oct 29, 2025 | Form 4 ↗ |
| Chawla Lakhmir SDirector | Grant / award | +181 | $3.87 | $700 | Feb 11, 2025 | Form 4 ↗ |
| CARVER JENNIFERDirector | Grant / award | +181 | $3.87 | $700 | Feb 11, 2025 | Form 4 ↗ |
| ROPER JESSDirector | Grant / award | +181 | $3.87 | $700 | Feb 11, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding REVB · SEC Form N-PORT
No mutual fund or ETF has reported REVB in an N-PORT filing in the last seven months.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Steven BoydSCHEDULE 13G/A · passive (13G) · 209.2K shares5.0%
Aug 14, 2026 · ↗ - Armistice Capital, LLCSCHEDULE 13G/A · passive (13G) · 209.2K shares5.0%
Aug 14, 2026 · ↗ - Steven BoydSCHEDULE 13G · passive (13G) · 323.2K shares7.8%
May 15, 2026 · ↗ - Armistice Capital, LLCSCHEDULE 13G · passive (13G) · 323.2K shares7.8%
May 15, 2026 · ↗ - AXA S.A.SCHEDULE 13G/A · passive (13G) · 56.0K shares0.9%
Feb 12, 2024 · ↗ - AXA Investment Managers S.A.SCHEDULE 13G/A · passive (13G) · 56.0K shares0.9%
Feb 12, 2024 · ↗ - AXA INVESTMENT MANAGERS UK LtdSCHEDULE 13G/A · passive (13G) · 56.0K shares0.9%
Feb 12, 2024 · ↗ - AXA Investment Managers ParisSCHEDULE 13G/A · passive (13G) · 56.0K shares0.9%
Feb 12, 2024 · ↗ - AXA IM Prime Impact GP S.a.r.lSCHEDULE 13G/A · passive (13G) · 56.0K shares0.9%
Feb 12, 2024 · ↗ - AXA IM Prime Impact Master Fund I SCA SICAV-RAIFSCHEDULE 13G/A · passive (13G) · 56.0K shares0.9%
Feb 12, 2024 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming REVELATION BIOSCIENCES, INC. as client
No lobbying filings found naming REVELATION BIOSCIENCES, INC. as the client.
Government Contracts
Federal awards to REVELATION BIOSCIENCES, INC. · USAspending
No federal contract awards found for REVELATION BIOSCIENCES, INC..
U.S. Patents
Recent USPTO applications naming REVELATION BIOSCIENCES, INC.
No USPTO patent applications found for REVELATION BIOSCIENCES, INC..
Annual Financials
From REVB's 10-K filings · XBRL
No annual XBRL figures on record for REVB. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-4Reverse splitJan 28, 2026
- 1-for-3Reverse splitJul 7, 2025
- 1-for-16Reverse splitJan 28, 2025
- 1-for-30Reverse splitJan 25, 2024
- 1-for-35Reverse splitFeb 1, 2023
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02, 9.01Officer / director changeAug 19, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.03, 5.03, 7.01, 9.01Material agreement · Modification of rights · Bylaw amendmentJul 13, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.03, 5.07, 9.01Officer / director change · Bylaw amendment · Shareholder voteJun 24, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗
About REVELATION BIOSCIENCES, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001810560 ↗
Former namesPetra Acquisition Inc.